BrainsWay's Upcoming Financial Report and Insights
BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 -- BrainsWay Ltd. (NASDAQ: BWAY), a pioneer in noninvasive neurostimulation treatments for mental health challenges, is gearing up to release its financial results for the third quarter of 2024. This much-anticipated announcement will be made before the market opens, specifically on Tuesday, November 12, 2024. In addition to the financial results, the company will offer operational highlights that showcase their growth and ongoing commitment to improving mental health treatments.
Conference Call Details
To provide more context and take questions from stakeholders, BrainsWay has scheduled a conference call and webcast for the same day. This interactive session will begin at 8:30 AM Eastern Time, allowing participants to engage with company executives and gain insights into the business operations and the significance of the financial results.
How to Join the Conference Call
Individuals wishing to participate can dial in using the following numbers:
For domestic participants in the United States, the number is 1-877-300-8521. For those calling internationally, the number is 1-412-317-6026. Participants based in Israel can reach the event at 1-80-921-2373. A special conference ID, 10193781, is required for access. For visual learners, a live webcast will be available. Attendees are encouraged to access the link on the company’s investor relations page at least 10 minutes prior to the call.
About BrainsWay’s Innovative Solutions
BrainsWay distinguishes itself in the mental health space with its pioneering Deep Transcranial Magnetic Stimulation (Deep TMS™) technology. This advanced treatment has received three FDA clearances, which are substantive evidence of its clinical efficacy. These indications cater to major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay's steadfast focus is on enhancing patient outcomes through innovative approaches and providing comprehensive treatment options.
Continued Commitment to Research and Development
Moreover, BrainsWay continues to expand its reach through ongoing clinical trials investigating Deep TMS effectiveness for additional psychiatric and neurological conditions. Their commitment helps solidify their reputation as a leader in this critical healthcare sector, empowering patients with access to cutting-edge treatment options redefining mental health care.
Company Contact Information
For further inquiries, Ido Marom, the Chief Financial Officer of BrainsWay, is available via email at Ido.Marom@BrainsWay.com. Also, for investor relations, Brian Ritchie from LifeSci Advisors can be contacted at britchie@lifesciadvisors.com.
Frequently Asked Questions
What financial results will BrainsWay report?
BrainsWay will report their financial results for the third quarter of 2024, including relevant operational highlights.
When will the conference call take place?
The conference call is scheduled for November 12, 2024, at 8:30 AM Eastern Time.
How can I participate in the conference call?
Participants can join the call by dialing the provided numbers or through the live webcast available on BrainsWay's investor relations website.
What is Deep TMS technology?
Deep TMS is an innovative, noninvasive treatment designed to enhance mental health by utilizing magnetic stimulation.
Who should I contact for more information?
For inquiries, you can contact Ido Marom, CFO of BrainsWay, or Brian Ritchie from LifeSci Advisors.